Anas Younes MD

Dr. Anas Younes leads AstraZeneca’s new Haematology R&D unit, with responsibilities spanning from early discoveries and target identification, to first-in-human clinical studies, to late-stage trials and drug approvals. He is a clinician-scientist and has spent more than 25 years caring for patients with lymphoma. Prior to joining AstraZeneca, he was at Memorial Sloan Kettering Cancer Center (MSKCC) where he served as the Chief of the Lymphoma Service, in addition to leading a laboratory focused on drug development for patients with lymphoid malignancies. Our lab was focused on accelerating the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Prior to MSKCC, he worked for 20 years at the University of Texas MD Anderson Cancer Center (MDACC) where he directed clinical and translational research in the Department of Lymphoma and Myeloma.

During his tenure in academia, he lead numerous clinical trials that advanced the field and resulted in the U.S. Food and Drug Administration's approval of two novel agents for patients with Hodgkin's lymphoma, including the first targeted drug for the treatment of Hodgkin lymphoma in more than three decades, and the approval of the first immune checkpoint inhibitor for lymphoma. During the same time, our groups’ efforts at MDACC and MSKCC resulted in 11 new approved indications for the treatment of patients with different types of lymphoid malignancies.

He has published more than 300 papers in peer-reviewed journals, served as the principal investigator of more than 60 clinical trials, including national and international multi-centre studies, and led two independent National Cancer Institute–funded Specialized Programs of Research Excellence at MDACC and MSKCC that focused on novel drug development for patients with lymphoma. He also led a Leukemia & Lymphoma Society-sponsored Specialized Center of Research program focusing on developing a second-generation CAR (chimeric antigen receptor) T-cell therapy for patients with blood cancers. He is a past member of the Scientific Advisory Board of the Lymphoma Research Foundation.